



**Prior Authorization
Dermatology – Vtama® (tapinarof 1% cream)**

Table of Contents	Product Identifier(s)
National Formulary Medical Necessity1	92265
Conditions Not Covered.....2	
Background.....2	
References2	
Revision History.....3	

INSTRUCTIONS FOR USE

The following Coverage Policy applies to health benefit plans administered by Cigna Companies. Certain Cigna Companies and/or lines of business only provide utilization review services to clients and do not make coverage determinations. References to standard benefit plan language and coverage determinations do not apply to those clients. Coverage Policies are intended to provide guidance in interpreting certain standard benefit plans administered by Cigna Companies. Please note, the terms of a customer’s particular benefit plan document [Group Service Agreement, Evidence of Coverage, Certificate of Coverage, Summary Plan Description (SPD) or similar plan document] may differ significantly from the standard benefit plans upon which these Coverage Policies are based. For example, a customer’s benefit plan document may contain a specific exclusion related to a topic addressed in a Coverage Policy. In the event of a conflict, a customer’s benefit plan document always supersedes the information in the Coverage Policies. In the absence of a controlling federal or state coverage mandate, benefits are ultimately determined by the terms of the applicable benefit plan document. Coverage determinations in each specific instance require consideration of 1) the terms of the applicable benefit plan document in effect on the date of service; 2) any applicable laws/regulations; 3) any relevant collateral source materials including Coverage Policies and; 4) the specific facts of the particular situation. Coverage Policies relate exclusively to the administration of health benefit plans. Coverage Policies are not recommendations for treatment and should never be used as treatment guidelines. In certain markets, delegated vendor guidelines may be used to support medical necessity and other coverage determinations.

National Formulary Medical Necessity

Cigna covers tapinarof 1% cream (Vtama®) as medically necessary when the following criteria are met for FDA Indications or Other Uses with Supportive Evidence:

Prior Authorization is recommended for prescription benefit coverage of Vtama. All approvals are provided for the duration noted below. Because of the specialized skills required for evaluation and diagnosis of individuals treated with Vtama as well as the monitoring required for adverse events, approval requires Vtama to be prescribed by or in consultation with a physician who specializes in the condition being treated.

FDA Indication(s)

1. **Plaque Psoriasis.** Approve 1 year if the individual meets ALL of the following criteria (A, B, C, D, and E):
 - A) Individual is ≥ 18 years of age; AND
 - B) Individual has psoriasis involvement estimated to affect ≤ 20% of the body surface area; AND
 - C) Individual meets one of the following criteria (i or ii):
 - i. Individual meets all of the following criteria (a, b, and c):
 - a) Individual has tried at least one medium-, medium-high, high-, and/or super-high potency prescription topical corticosteroid; AND
 - b) This topical corticosteroid was applied daily for at least 4 consecutive weeks; AND

- c) Inadequate efficacy was demonstrated with this topical corticosteroid, according to the prescriber; OR
- ii. Individual is treating psoriasis affecting one of the following areas: face, eyes/eyelids, skin folds, and/or genitalia; AND
- D) Individual meets ALL of the following criteria (i, ii, and iii):
 - i. Individual has tried at least one topical vitamin D analog; AND
Note: Examples of topical vitamin D analogs include calcipotriene 0.005% foam (Sorilux, authorized generic), calcipotriene 0.005% cream (Dovonex, generic), calcipotriene 0.005% ointment (generic only), calcitriol 3 mcg/g ointment (Vectical, generic), calcipotriene 0.005% and betamethasone dipropionate 0.064% foam (Enstilar), calcipotriene 0.005% and betamethasone dipropionate 0.064% cream (Wynzora), calcipotriene 0.005% and betamethasone dipropionate 0.064% ointment (Taclonex, generic), calcipotriene 0.005% and betamethasone dipropionate 0.064% suspension (Taclonex, generic). Concomitant use of a topical vitamin D analog and a topical corticosteroid would meet the requirement
 - ii. This topical vitamin D analog was applied daily for at least 4 consecutive weeks; AND
 - iii. Inadequate efficacy was demonstrated with this topical vitamin D analog, according to the prescriber; AND
- E) The medication is prescribed by or in consultation with a dermatologist.

Conditions Not Covered

Tapinarof 1% cream (Vtama®) is considered experimental, investigational or unproven for ANY other use.

Background

Overview

Vtama, an aryl hydrocarbon receptor agonist, is indicated for the topical treatment of **plaque psoriasis** in adults.¹ The pivotal studies enrolled patients with plaque psoriasis, with a body surface area involvement of 3% to 20%.²

Guidelines

The mainstay of treatment of plaque psoriasis is topical therapy, including corticosteroids, vitamin D analogs, calcineurin inhibitors, keratolytics (e.g., tazarotene), and combination therapies (e.g., a corticosteroid with a vitamin D analog).³ Joint guidelines from the American Academy of Dermatology (AAD) and the Medical Board of the National Psoriasis Foundation (NPF) [2021] have been published for the management of psoriasis with topical therapies.⁴ Vtama is not yet addressed in the guidelines. Use of a topical corticosteroid for up to 4 weeks is recommended for plaque psoriasis not involving intertriginous areas (strength of recommendation, A). A topical vitamin D analog can be used long-term (up to 52 weeks) for the treatment of psoriasis [strength of recommendation, A]. Guidelines also address use of topical calcineurin inhibitors, topical tazarotene, topical salicylic acid, and phototherapy.

References

1. Vtama® topical cream [prescribing information]. Long Beach, CA: Dermavant; May 2022.
2. Lebwohl MG, Stein Gold L, Strober B, et al. Phase 3 trials of tapinarof cream for plaque psoriasis. *N Eng J Med.* 2021;385:2219-2229.
3. Griffiths CEM, Armstrong AW, Gudjonsson JE, Barker JNWN. Psoriasis. *Lancet.* 2021;397:1301-1315
4. Elmets C, Korman NJ, Farley Prater E, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures. *J Am Acad Dermatol.* 2021;84:432-470.

Revision History

Type of Revision	Summary of Changes	Approval Date
New Policy	--	06/01/2022

"Cigna Companies" refers to operating subsidiaries of Cigna Corporation. All products and services are provided exclusively by or through such operating subsidiaries, including Cigna Health and Life Insurance Company, Connecticut General Life Insurance Company, Evernorth Behavioral Health, Inc., Cigna Health Management, Inc. and HMO or service company subsidiaries of Cigna Health Corporation. The Cigna name, logo, and other Cigna marks are owned by Cigna Intellectual Property, Inc. © 2022 Cigna.